The_role_of_endogenous_gonadotropin_release_in_the_etiology_of_ovarian_enlargement_during_purified_urinary_follicle-stimulating_hormone_therapy._Patients_with_polycystic_ovarian_disease_were_grouped_into_three_groups_according_to_their_maximum_ovarian_diameter_(maxD)_after_ovulation_induction_by_purified_urinary_follicle-stimulating_hormone_(FSH)._Serum_luteinizing_hormone_(LH)_and_FSH_were_measured_daily_by_radioimmunoassay_and_size_and_number_of_follicles_were_assessed_by_ultrasonography._Follicle-stimulating_hormone_in_group_A_(80_mm_less_than_or_equal_to_maxD)_was_significantly_higher_than_those_of_group_B_(60_mm_less_than_or_equal_to_maxD_less_than_80_mm)_and_C_(maxD_less_than_60_mm)_for_the_last_4_days_of_the_treatment._This_FSH_rise_in_group_A_was_not_accounted_for_by_FSH_accumulation_by_the_study_of_pharmacodynamics,_and_so_was_thought_to_be_of_endogenous_origin._Luteinizing_hormone_was_also_elevated_3_days_before_the_administration_of_human_chorionic_gonadotropin_(hCG)_in_both_groups_A_and_B._The_number_of_follicles_in_group_A_at_hCG_administration_was_significantly_greater_than_that_of_group_C._Any_significant_differences_were_not_found_in_either_total_amount_of_purified_urinary_FSH_or_in_the_basal_FSH_and_the_LH_levels_before_treatment_of_the_three_groups._These_results_suggest_that_excessive_ovarian_enlargement_during_gonadotropin_therapy_is_caused_by_multiple_follicular_development_primarily_stimulated_by_endogenous_FSH._Endogenous_LH_release_further_enhances_ovarian_enlargement.